|
US6858712B1
(en)
|
1984-08-22 |
2005-02-22 |
The United States Of America As Represented By The Department Of Health And Human Services |
Cloning and expression of HTLV-III DNA
|
|
US6174666B1
(en)
|
1992-03-27 |
2001-01-16 |
The United States Of America As Represented By The Department Of Health And Human Services |
Method of eliminating inhibitory/instability regions from mRNA
|
|
WO1996004386A1
(en)
|
1994-08-05 |
1996-02-15 |
Warner-Lambert Company |
Method of using transdominant negative retroviral integrase in the treatment of retroviral infection
|
|
US7488485B2
(en)
|
2003-09-16 |
2009-02-10 |
University Of Kansas Medical Center |
DNA vaccine compositions and methods of use
|
|
DE19856463B4
(de)
|
1998-11-26 |
2006-02-02 |
Heinrich-Pette-Institut |
Retrovirale, mit LCMV pseudotypisierte Hybrid-Vektoren
|
|
US7935805B1
(en)
|
1998-12-31 |
2011-05-03 |
Novartis Vaccines & Diagnostics, Inc |
Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
|
|
AU2487300A
(en)
|
1998-12-31 |
2000-07-31 |
Chiron Corporation |
Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
|
|
AUPQ776100A0
(en)
|
2000-05-26 |
2000-06-15 |
Australian National University, The |
Synthetic molecules and uses therefor
|
|
CA2458995C
(en)
|
2001-08-31 |
2013-04-30 |
Chiron Corporation |
Polynucleotides encoding antigenic hiv type b polypeptides, polypeptides and uses thereof
|
|
US20070077257A1
(en)
|
2001-09-14 |
2007-04-05 |
Emini Emilio A |
Enhanced first generation adenovirus vaccines expressing condon optimized HIV1-Gag, Pol, Nef and modifications
|
|
US7195768B2
(en)
|
2001-11-07 |
2007-03-27 |
Duke University |
Polyvalent immunogen
|
|
WO2003039470A2
(en)
|
2001-11-07 |
2003-05-15 |
Duke University |
Polyvalent immunogen of hiv
|
|
US7172761B2
(en)
|
2001-11-07 |
2007-02-06 |
Duke University |
Polyvalent immunogen
|
|
EP1456376A4
(en)
|
2001-11-16 |
2006-09-06 |
Us Gov Health & Human Serv |
NEW CHIMERAL REV, TAT AND NEF ANTIGENES
|
|
GB0225788D0
(en)
|
2002-11-05 |
2002-12-11 |
Glaxo Group Ltd |
Vaccine
|
|
ATE520708T1
(de)
|
2003-03-28 |
2011-09-15 |
Us Gov Health & Human Serv |
Immunogenetische hiv-1 multi-klade, multivalente konstrukte und deren verwendung
|
|
BRPI0414443A
(pt)
|
2003-09-17 |
2006-11-21 |
Univ Duke |
imunógenos consensuais/ancestrais
|
|
WO2005028634A2
(en)
|
2003-09-18 |
2005-03-31 |
Emory University |
Improved mva vaccines
|
|
GB2406336A
(en)
|
2003-09-24 |
2005-03-30 |
Oxxon Pharmaccines Ltd |
HIV Pharmaccines
|
|
AU2004276559A1
(en)
|
2003-09-24 |
2005-04-07 |
Oxxon Therapeutics Limited |
HIV pharmaccines
|
|
GB0417494D0
(en)
|
2004-08-05 |
2004-09-08 |
Glaxosmithkline Biolog Sa |
Vaccine
|
|
BRPI0514447B8
(pt)
|
2004-08-17 |
2021-05-25 |
Centre Nat Rech Scient |
uso da função imunosupressora de uma proteína acessória do vírus da imunodeficiência humana ou do símio para a preparação de uma vacina
|
|
US8000900B2
(en)
|
2004-09-21 |
2011-08-16 |
Microsoft Corporation |
Association-based predictions of pathogen characteristics
|
|
US8478535B2
(en)
|
2004-10-29 |
2013-07-02 |
Microsoft Corporation |
Systems and methods that utilize machine learning algorithms to facilitate assembly of aids vaccine cocktails
|
|
EP1856143A2
(en)
|
2005-02-24 |
2007-11-21 |
Medical Research Council |
Hivcon: anhiv immunogen and uses thereof
|
|
ES2281252B1
(es)
|
2005-07-27 |
2009-02-16 |
Consejo Superior De Investigaciones Cientificas |
Vectores recombinantes basados en el virus modificado de ankara (mva) como vacunas preventivas y terapeuticas contra el sida.
|
|
CN101969996A
(zh)
|
2005-08-23 |
2011-02-09 |
加利福尼亚大学董事会 |
多价疫苗
|
|
US7951377B2
(en)
|
2005-08-23 |
2011-05-31 |
Los Alamos National Security, Llc |
Mosaic clade M human immunodeficiency virus type 1 (HIV-1) envelope immunogens
|
|
DK2029168T3
(da)
|
2006-06-02 |
2013-01-14 |
Int Aids Vaccine Initiative |
HIV-1 Clade A konsensussekvenser, antigener og transgener.
|
|
CA3057039C
(en)
|
2006-07-28 |
2023-02-28 |
The Trustees Of The University Of Pennsylvania |
Hiv consensus envelope sequences and methods for using same
|
|
US8452541B2
(en)
|
2007-06-18 |
2013-05-28 |
Microsoft Corporation |
Vaccine design methodology
|
|
US8452542B2
(en)
|
2007-08-07 |
2013-05-28 |
Lawrence Livermore National Security, Llc. |
Structure-sequence based analysis for identification of conserved regions in proteins
|
|
SI2604695T1
(sl)
|
2007-12-27 |
2023-03-31 |
Universitaet Zuerich Prorektorat Forschung |
Replikacijsko defektni arenavirusni vektorji
|
|
NZ602504A
(en)
|
2008-11-18 |
2014-01-31 |
Beth Israel Hospital |
Antiviral vaccines with improved cellular immunogenicity
|
|
WO2011019932A2
(en)
|
2009-08-14 |
2011-02-17 |
Theraclone Sciences, Inc. |
Compositions and methods for the therapy and diagnosis of influenza
|
|
MX2012011189A
(es)
|
2010-03-26 |
2013-02-07 |
Glaxosmithkline Biolog Sa |
Vacuna contra el virus e inmunodeficiencia humana.
|
|
CA2833425C
(en)
|
2011-04-07 |
2018-08-21 |
Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Health |
Protease cleavage site peptides as an hiv vaccine
|
|
GB201122297D0
(en)
|
2011-12-23 |
2012-02-01 |
Retroscreen Virology Ltd |
Vaccine - screening method
|
|
EP2620446A1
(en)
|
2012-01-27 |
2013-07-31 |
Laboratorios Del Dr. Esteve, S.A. |
Immunogens for HIV vaccination
|
|
US9501614B2
(en)
|
2012-05-22 |
2016-11-22 |
Indiana University Research And Technology Corporation |
Method for computer-aided vaccine discovery
|
|
WO2013188886A2
(en)
|
2012-06-15 |
2013-12-19 |
California Institute Of Technology |
Method and system for parallel batch processing of data sets using gaussian process with batch upper confidence bound
|
|
WO2014026033A1
(en)
|
2012-08-08 |
2014-02-13 |
University Of Florida Research Foundation, Inc. |
Cross-reactive t cell epitopes of hiv, siv, and fiv for vaccines in humans and cats
|
|
WO2014036488A1
(en)
|
2012-08-31 |
2014-03-06 |
Biovest International, Inc. |
Methods for producing high-fidelity autologous idiotype vaccines
|
|
CA2884859C
(en)
|
2012-09-12 |
2024-06-18 |
Duke University |
Hiv-1 antibody evolution immunogens
|
|
TWI626948B
(zh)
|
2013-03-26 |
2018-06-21 |
環球免疫公司 |
治療或預防人類免疫缺乏病毒感染之組合物及方法
|
|
US9732121B2
(en)
|
2013-09-25 |
2017-08-15 |
The Board Of Trustees Of The Leland Stanford Junior University |
Rational vaccine design for hepatitis C virus
|
|
ES2957209T3
(es)
*
|
2013-09-30 |
2024-01-15 |
Triad Nat Security Llc |
Polipéptidos inmunogénicos mosaicos del VIH de región conservada
|
|
WO2015048796A2
(en)
|
2013-09-30 |
2015-04-02 |
Los Alamos National Security, Llc |
Mosaic hiv envelope immunogenic polypeptides
|
|
CN106999571B
(zh)
|
2014-09-26 |
2020-10-02 |
贝斯以色列护理医疗中心有限公司 |
诱导针对人免疫缺陷病毒感染的保护性免疫性的方法和组合物
|
|
MA40783A
(fr)
|
2014-10-03 |
2017-08-08 |
Los Alamos Nat Security Llc |
Vaccins contre le vih comprenant un ou plusieurs antigènes episensus de population
|
|
SI3218504T1
(sl)
|
2014-11-13 |
2020-11-30 |
Universite De Geneve |
Tri-segmentirani arenavirusi kot vakcinski vektorji
|
|
US10421788B2
(en)
|
2015-09-10 |
2019-09-24 |
The General Hospital Corporation |
Synthesizing vaccines, immunogens, and antibodies
|
|
CA2997955A1
(en)
|
2015-09-15 |
2017-03-23 |
Gilead Sciences, Inc. |
Modulators of toll-like receptors for the treatment of hiv
|
|
ES2970865T3
(es)
|
2015-12-16 |
2024-05-31 |
Gritstone Bio Inc |
Identificación, fabricación y uso de neoantígenos
|
|
IL262963B2
(en)
|
2016-05-18 |
2025-01-01 |
Hookipa Biotech Gmbh |
Trisegmented PICHINDE viruses as vaccine vectors
|
|
WO2018075559A1
(en)
|
2016-10-17 |
2018-04-26 |
Beth Israel Deaconess Medical Center, Inc. |
Signature-based human immunodeficiency virus (hiv) envelope (env) trimer vaccines and methods of using the same
|
|
JP2020500552A
(ja)
|
2016-11-23 |
2020-01-16 |
グリットストーン オンコロジー インコーポレイテッド |
新生抗原のウイルスによる送達方法
|
|
KR20260047644A
(ko)
|
2017-03-30 |
2026-04-08 |
더 유니버서티 어브 퀸슬랜드 |
키메라 분자 및 그의 용도
|
|
CA3060569A1
(en)
|
2017-04-19 |
2018-10-25 |
Gritstone Oncology, Inc. |
Neoantigen identification, manufacture, and use
|
|
EP3634449A4
(en)
|
2017-05-08 |
2021-03-17 |
Gritstone Oncology, Inc. |
ALPHAVIRUS NEOANTIGEN VECTORS
|
|
AU2018279627B2
(en)
|
2017-06-09 |
2023-08-10 |
Seattle Project Corp. |
Neoantigen identification, manufacture, and use
|
|
US20210147550A1
(en)
|
2017-08-18 |
2021-05-20 |
Joshua Michael Francis |
Antigen-binding proteins targeting shared antigens
|
|
US20200363414A1
(en)
|
2017-09-05 |
2020-11-19 |
Gritstone Oncology, Inc. |
Neoantigen Identification for T-Cell Therapy
|
|
WO2019070730A1
(en)
|
2017-10-02 |
2019-04-11 |
Duke University |
MOSAIC ENVELOPES OF HIV-1 TO INDUCE ADCC RESPONSES
|
|
EP4576103A3
(en)
|
2017-10-10 |
2025-08-27 |
Gritstone bio, Inc. |
Neoantigen identification using hotspots
|
|
CN111630602A
(zh)
|
2017-11-22 |
2020-09-04 |
磨石肿瘤生物技术公司 |
减少新抗原的接合表位呈递
|
|
EP3731876A4
(en)
|
2017-12-28 |
2022-04-06 |
Gritstone bio, Inc. |
ANTIGEN-BINDING PROTEINS TARGETING SHARED ANTIGENS
|
|
KR20220041844A
(ko)
|
2019-07-02 |
2022-04-01 |
그릿스톤 바이오, 인코포레이티드 |
Hiv 항원 및 mhc 복합체
|
|
KR20240137107A
(ko)
|
2019-07-16 |
2024-09-19 |
길리애드 사이언시즈, 인코포레이티드 |
Hiv 백신, 및 이의 제조 및 사용 방법
|
|
US12559527B2
(en)
|
2019-10-23 |
2026-02-24 |
Duke University |
Compositions comprising V2 opt HIV envelopes
|
|
WO2022006095A2
(en)
|
2020-06-29 |
2022-01-06 |
Duke University |
Mosaic hiv-1 envelopes to induce adcc responses
|
|
WO2023064424A2
(en)
|
2021-10-12 |
2023-04-20 |
Duke University |
Compositions comprising v2 opt hiv envelopes
|